SEATTLE


,


April 28, 2022


/PRNewswire/ — CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2022 financial results on

Thursday, May 12, 2022

, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at

4:30 p.m. ET

(

1:30 p.m. PT

).

To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 7291915. A live audio webcast of the event may also be accessed through the “Investors” section of CTI’s website at

www.ctibiopharma.com

. A replay of the webcast will be available for 30 days following the event.

About CTI BioPharma Corp.


We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO™ (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10

⁹

/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO™ is a trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts:


Argot Partners

+212-600-1902


[email protected]

View original content to download multimedia:

https://www.prnewswire.com/news-releases/cti-biopharma-to-report-first-quarter-2022-financial-results-on-may-12-2022-301535837.html

SOURCE CTI BioPharma Corp.